 Connection
Peter Fecci to Glioma
This is a "connection" page, showing publications Peter Fecci has written about Glioma.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
4.284 |
|
|
|
-
Mariani CL, Wachsmuth LP, Bramall AN, Meritet DM, Hatfield J, Tsvankin V, Keenihan EK, Tokarz DA, Tyc R, Nolan MW, Fecci PE. Adapting Laser Interstitial Thermal Therapy for the Treatment of Naturally Occurring Intracranial Tumors in Dogs. Clin Cancer Res. 2025 Oct 15; 31(20):4372-4382.
Score: 0.661
-
Srinivasan ES, Tsvankin V, Fecci PE. Commentary: A Neurosurgeon's Guide to Cognitive Dysfunction in Adult Glioma. Neurosurgery. 2021 06 15; 89(1):E1-E2.
Score: 0.490
-
Grabowski MM, Sankey EW, Ryan KJ, Chongsathidkiet P, Lorrey SJ, Wilkinson DS, Fecci PE. Immune suppression in gliomas. J Neurooncol. 2021 Jan; 151(1):3-12.
Score: 0.457
-
Woroniecka KI, Rhodin KE, Dechant C, Cui X, Chongsathidkiet P, Wilkinson D, Waibl-Polania J, Sanchez-Perez L, Fecci PE. 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers. Clin Cancer Res. 2020 03 15; 26(6):1349-1358.
Score: 0.442
-
Fecci PE, Sampson JH. The current state of immunotherapy for gliomas: an eye toward the future. J Neurosurg. 2019 09 01; 131(3):657-666.
Score: 0.433
-
Fecci PE, Babu R, Adamson DC, Sampson JH. Editorial: Turning fluorescence into black and white. J Neurosurg. 2015 Jun; 122(6):1356-8.
Score: 0.319
-
Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, Cummings T, Allison JP, Bigner DD, Sampson JH. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res. 2007 Apr 01; 13(7):2158-67.
Score: 0.183
-
Fecci PE, Sweeney AE, Grossi PM, Nair SK, Learn CA, Mitchell DA, Cui X, Cummings TJ, Bigner DD, Gilboa E, Sampson JH. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 1):4294-305.
Score: 0.174
-
Singh K, Foster MW, Violette MJ, Corcoran AM, Hotchkiss KM, Railton CO, Blandford EE, Blethen KE, Thomas EL, McIntosh WC, Ashley DM, Desjardins A, Friedman HS, Johnson MO, Friedman A, Keir S, Buckley ED, Herndon JE, McLendon RE, Sampson JH, Calabrese E, López GY, Grant GA, Patel AP, Gregory SG, Li CY, Fecci PE, Khasraw M. A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma. Sci Rep. 2025 Oct 23; 15(1):37112.
Score: 0.166
-
Mehari M, Warrier G, Dada A, Kabir A, Haskell-Mendoza AP, Tripathy A, Jha R, Nieblas-Bedolla E, Jackson JD, Gonzalez AT, Reason EH, Flusche AM, Reihl S, Dalton T, Negussie M, Gonzales CN, Ambati VS, Desjardins A, Daniel AGS, Krishna S, Chang S, Porter A, Fecci PE, Hollon T, Chukwueke UN, Badal K, Molinaro AM, Hervey-Jumper SL. Predicting therapeutic clinical trial enrollment for adult patients with low- and high-grade glioma using supervised machine learning. Sci Adv. 2025 Jun 06; 11(23):eadt5708.
Score: 0.161
-
Hotchkiss KM, Karschnia P, Schreck KC, Geurts M, Cloughesy TF, Huse J, Duke ES, Lathia J, Ashley DM, Nduom EK, Long G, Singh K, Chalmers A, Ahluwalia MS, Heimberger A, Bagley S, Todo T, Verhaak R, Kelly PD, Hervey-Jumper S, de Groot J, Patel A, Fecci P, Parney I, Wykes V, Watts C, Burns TC, Sanai N, Preusser M, Tonn JC, Drummond KJ, Platten M, Das S, Tanner K, Vogelbaum MA, Weller M, Whittle JR, Berger MS, Khasraw M. A brave new framework for glioma drug development. Lancet Oncol. 2024 10; 25(10):e512-e519.
Score: 0.154
-
Fecci PE, Gromeier M, Sampson JH. Viruses in the treatment of brain tumors. Neuroimaging Clin N Am. 2002 Nov; 12(4):553-70.
Score: 0.135
-
Fecci PE, Sampson JH. Clinical immunotherapy for brain tumors. Neuroimaging Clin N Am. 2002 Nov; 12(4):641-64.
Score: 0.135
-
Gedeon PC, Riccione KA, Fecci PE, Sampson JH. Antibody-based immunotherapy for malignant glioma. Semin Oncol. 2014 Aug; 41(4):496-510.
Score: 0.075
-
Dunn GP, Fecci PE, Curry WT. Cancer immunoediting in malignant glioma. Neurosurgery. 2012 Aug; 71(2):201-22; discussion 222-3.
Score: 0.066
-
Agarwalla P, Barnard Z, Fecci P, Dranoff G, Curry WT. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J Immunother. 2012 Jun; 35(5):385-9.
Score: 0.065
-
Selznick LA, Shamji MF, Fecci P, Gromeier M, Friedman AH, Sampson J. Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines. Neurosurg Rev. 2008 Apr; 31(2):141-55; discussion 155.
Score: 0.049
-
Learn CA, Fecci PE, Schmittling RJ, Xie W, Karikari I, Mitchell DA, Archer GE, Wei Z, Dressman H, Sampson JH. Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers. Clin Cancer Res. 2006 Dec 15; 12(24):7306-15.
Score: 0.045
-
Zachem TJ, Sperber JE, Chen SF, Adil SM, Wissel BD, Chamberlin G, Owolo E, Nguyen A, Crowell KA, Herndon JE, Abi Hachem R, Jang DW, Cummings TJ, Johnson MO, Eward W, Patel AP, Komisarow JM, Cook SH, Southwell D, Fecci PE, Friedman AH, Goodwin CR, Codd PJ. Intraoperative brain tumor classification via laser-induced fluorescence spectroscopy and machine learning. J Neurosurg. 2025 Aug 01; 143(2):313-322.
Score: 0.040
-
Mitchell DA, Fecci PE, Sampson JH. Adoptive immunotherapy for malignant glioma. Cancer J. 2003 May-Jun; 9(3):157-66.
Score: 0.035
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|